Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b study of bevacizumab + temsirolimus vs bevacizumab + interferon alfa in advanced renal cell carcinoma
2007-003793-26Phase 3Completed
- Sponsor
- Wyeth
- Start
- Mar 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in clear cell renal cell carcinoma (ccRCC) and metastatic renal cell carcinoma (mRCC) comparing Bevacizumab + temsirolimus with Bevacizumab + interferon alfa-2a (2 arms). Primary endpoint: Independently assessed progression-free survival. Started Mar 2008; status: completed.
02
Drugs
bevacizumabtemsirolimusinterferon alfa-2a
03
Conditions
clear cell renal cell carcinoma (ccRCC)metastatic renal cell carcinoma (mRCC)
Beyond the preview
Go deeper on 2007-003793-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003793-26.